Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: 12 Erazma Ciołka Str, 01-402 Warsaw
,Poland
Tel: +48 22 254 24 84
ClinMed Pharma is a Polish Clinical Research Organization cooperating with pharmaceutical, CRO and biotech companies in all phases of clinical trials, as well as non-interventional studies.
Our mission is to provide high quality services with much personal attention and to customise the services to the needs of our clients.
ClinMed Pharma personnel show great commitment to all projects not only ensuring the proper study conduct required by the local law, GCP standards and Sponsor’s SOPs but also good and long-term relationships with investigators due to the professional and reliable approach.
ClinMed Pharma is experienced in site contract negotiation as well as submission of Clinical Trial Application to Regulatory Authority and Ethics Committee.
Moving to the next step of the project, our CRAs perform all activities necessary for ongoing monitoring of the study with great focus on quality. As far as audit preparation is concerned, our staff has the medical, technical and regulatory expertise to ensure that standards, processes and personnel are in place to achieve the highest quality. We also deliver training increasing the quality pivotal for the conduct of clinical studies.
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here